Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($0.60), $0.17 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $66.41 million versus the consensus estimate of $57.53 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.